Rationale: Myositis-specific autoantibodies (MSAs) provide the basis for the diagnosis of IIM-
ILD and have been implicated in disease pathogenesis. In clinical practice, MSA levels are …

Objectives The detection of myositis autoantibodies (MA) in patients with interstitial lung
disease (ILD) has major implications for diagnosis and management, especially amyopathic …

PURPOSE: Interstitial lung disease (ILD) is seen in 5-40% of patients with autoimmune
myositis. Myositis autoantibodies panel (including Anti-Jo-1, PL-7, PL-12, EJ, OJ, SRP, MI-2 …

We read with interest the recent article from Fidler et al.[1] published online in LUNG (March
2019) and the previous article from De Sadeleer et al.[2](March 2018) examining the role of …

Interstitial lung disease (ILD) frequently complicates the inflammatory myopathies and at
times is the most prominent clinical feature. Over the years, there has been a growing …

Objective To evaluate the role of myositis-specific autoantibodies (MSAs) in interstitial lung
disease (ILD), management of idiopathic inflammatory myopathies (IIM) associated ILD, and …

Abstract Purpose of Review To review advances in the management of idiopathic
inflammatory myopathy-associated interstitial lung disease (IIM-associated ILD) in the past 5 …

Connective tissue diseases (CTDs) are an important secondary cause of interstitial lung
disease (ILD). If a CTD is suspected, clinicians are recommended to perform autoantibody …

Rationale: The American Thoracic Society recommends patients with interstitial lung
disease (ILD) be screened for connective tissue disease with anti-nuclear antibodies (ANA) …

Although interstitial lung disease (ILD) is a leading cause of morbidity and mortality in
patients with inflammatory myopathies, the current definition and diagnostic criteria of …